Biofrontera (BFRA) Stock Price, News & Analysis

Company Overview

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Key Stats

• Today's Range: $2.51 to $2.78
• 50-Day Range: $2.50 to $3.60
• 52-Week Range: $2.09 to $7.54
• Volume: 7,263 shs
• Average Volume: 27,512 shs
• Market Capitalization: $73.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BFRA Stock Analysis - Frequently Asked Questions

How were Biofrontera's earnings last quarter?

Biofrontera AG (NASDAQ:BFRA) posted its earnings results on Wednesday, November, 24th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.03. The firm had revenue of $6.34 million for the quarter. Biofrontera had a negative trailing twelve-month return on equity of 93.31% and a negative net margin of 59.44%.

When did Biofrontera IPO?

Biofrontera (BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include AMC Entertainment (AMC), AC Immune (ACIU), Adaptimmune Therapeutics (ADAP), ADMA Biologics (ADMA), Ashford Hospitality Trust (AHT), Akebia Therapeutics (AKBA) and Assembly Biosciences (ASMB).

Company Calendar

• Last Earnings: 11/24/2021
• Today: 5/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BFRA
• CIK: 1712641
• Web: www.biofrontera.com
• Phone: (921) 487-6320
• Fax: 49-02-1487-6320
• Employees: 138
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.88 million
• Net Margins: -59.44%
• Pretax Margin: N/A
• Return on Equity: -93.31%
• Return on Assets: -24.02%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.26
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: $36.19 million
• Price / Sales: 2.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 7.43

Miscellaneous

• Outstanding Shares: 28,359,000
• Free Float: N/A
• Market Cap: $73.73 million
• Optionable: Not Optionable
• Beta: 1.02